CA Patent

CA3009169A1 — Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)

Assigned to Neurocrine Biosciences Inc · Expires 2017-06-29 · 9y expired

What this patent protects

Provided herein are processes for the preparation of (5)-(27?,37?,llb7?)-3-isobutyl-9,10- dimethoxy-2,3,4,6,7,llb-hexahydro-lH-pyrido[2,l-a]isoquinolin-2-yl 2-amino-3- methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof, useful for treatment …

USPTO Abstract

Provided herein are processes for the preparation of (5)-(27?,37?,llb7?)-3-isobutyl-9,10- dimethoxy-2,3,4,6,7,llb-hexahydro-lH-pyrido[2,l-a]isoquinolin-2-yl 2-amino-3- methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof, useful for treatment of hyperkinetic movement disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA3009169A1
Jurisdiction
CA
Classification
Expires
2017-06-29
Drug substance claim
No
Drug product claim
No
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.